Radium injections for prostate cancer full#
Radium injections for prostate cancer trial#

Patient characteristics and safety of radium-223 dichloride in Taiwan: Analysis of real-world clinical practice. A follow-up observation up to 2 years after initial injection is currently ongoing. The relatively low rate of treatment-related adverse events and lack of new safety concerns presented in this study demonstrates the safety of radium-223 under routine clinical practice in Taiwan treating bone metastases related to castration-resistant prostate cancer, according to the poster. Xofigo (Radium-223) injection is used for the treatment of symptomatic, metastatic, castration-resistant prostate cancer (mCRCP). Prostate brachytherapy involves placing radioactive sources in the prostate gland, where the radiation can kill the cancer cells while causing less damage to healthy tissue nearby.

The most common treatment-related adverse events were hematological events (9.3%) and diarrhea (8.2%), bone pain (7.2%) and decreased appetite (7.2%). Prostate brachytherapy (brak-e-THER-uh-pee) is a form of radiation therapy used to treat prostate cancer. In addition, 5% of patients in the second-line cohort and 12% of patients in the third-line cohort died before completing the injection course. The most common reasons for treatment discontinuation of patients in this study were patient decision (9.3%), disease progression (12.4%), and adverse events (6.2%). Total alkaline phosphatase levels decreased in 77% of patients in the first-line group, 82% in the second-line group and 60% in the third-line group, underscoring the enhanced efficacy of radium-223 as a front-line therapy, according to the researchers. In patients treated in the first-line setting, 36.4% experienced decreased PSA levels compared with 20% of patients in the second-line cohort and 14% in the third-line cohort. The most common reason for treatment discontinuation was disease progression (12% n = 12).

Radium injections for prostate cancer full#

Of note, 55% of patients received a full course (6 injections) of radium-223 injections, and 67% received 5 of the 6 injections. Previous lines of therapy included abiraterone and/or enzalutamide (Xtandi) (72.2% n = 70) as well as docetaxel (34% n = 33). Indicated for treatment of men with castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease 55 kBq (1.49 microcurie) per kg IV infused. Of these patients, 22 received radium-223 as first-line treatment, 42 as second-line treatment, and 33 as third-line treatment.

Radium injections for prostate cancer trial#

Although researchers assessed treatment with radium-223 in the first-, second-, and third-line settings, patients treated in the first-line setting had fewer treatment-related adverse events and higher rates of treatment completion with 6 injections.Ī total of 224 patients were included in the multicenter observational trial in Taiwan, of whom 97 were in the safety analysis set.